{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:08:30Z","timestamp":1776406110468,"version":"3.51.2"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s00228-026-04014-w","type":"journal-article","created":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T02:18:09Z","timestamp":1774491489000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of early use of PCSK9 inhibitors in acute ischemic stroke: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"82","author":[{"given":"Khadeeja Ali","family":"Hamzah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yousif Hameed","family":"Kurmasha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammedsadeq A.","family":"Shweliya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Saad","family":"Al-Shammari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid Radwan","family":"Alsaadany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdallah Adel","family":"Nofal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah Muataz Taha","family":"Al-Ibraheem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Sermed","family":"Al Sakini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nihar","family":"Jena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharmeen","family":"Naz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moinuddin","family":"Syed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melaku","family":"Demede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasar","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,26]]},"reference":[{"key":"4014_CR1","doi-asserted-by":"publisher","unstructured":"Barlow B, Webb AJ, Berger K (2025) Acute Ischemic Stroke. In: Alzaidi Y, Gebily MA, editors. The Pharmacist\u2019s Expanded Role in Critical Care Medicine [Internet]. Cham: Springer Nature Switzerland; [cited 2025 Sept 16]. pp. 437\u201370. Available from: https:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/978-3-031-77335-8_17","DOI":"10.1007\/978-3-031-77335-8_17"},{"key":"4014_CR2","doi-asserted-by":"publisher","unstructured":"Otite FO, Liaw N, Khandelwal P, Malik AM, Romano JG, Rundek T et al (2017) Increasing prevalence of vascular risk factors in patients with stroke: A call to action. Neurology [Internet] 89(19):1985\u201394. Available from: https:\/\/www.neurology.org\/doi\/https:\/\/doi.org\/10.1212\/WNL.0000000000004617","DOI":"10.1212\/WNL.0000000000004617"},{"key":"4014_CR3","doi-asserted-by":"crossref","unstructured":"Verburgt E, Hilkens NA, Ekker MS, Schellekens MMI, Boot EM, Immens MHM et al (2024) Short-Term and Long-Term Risk of Recurrent Vascular Event by Cause After Ischemic Stroke in Young Adults. JAMA Netw Open [Internet] 7(2):e240054. Available from: https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2815279","DOI":"10.1001\/jamanetworkopen.2024.0054"},{"key":"4014_CR4","doi-asserted-by":"crossref","unstructured":"Koren-Morag N (2002) Low- and High-Density Lipoprotein Cholesterol and Ischemic Cerebrovascular DiseaseThe Bezafibrate Infarction Prevention Registry. Arch Intern Med [Internet] 162(9):993. Available from: http:\/\/archinte.jamanetwork.com\/article.aspx?doi=10.1001\/archinte.162.9.993","DOI":"10.1001\/archinte.162.9.993"},{"key":"4014_CR5","doi-asserted-by":"crossref","unstructured":"Lee M, Cheng CY, Wu YL, Lee JD, Hsu CY, Ovbiagele B (2022) Association Between Intensity of Low-Density Lipoprotein Cholesterol Reduction With Statin-Based Therapies and Secondary Stroke Prevention: A Meta-analysis of Randomized Clinical Trials. JAMA Neurol [Internet] 79(4):349. Available from: https:\/\/jamanetwork.com\/journals\/jamaneurology\/fullarticle\/2789410","DOI":"10.1001\/jamaneurol.2021.5578"},{"key":"4014_CR6","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1161\/ATV.0000000000000164","volume":"43","author":"LB Goldstein","year":"2023","unstructured":"Goldstein LB, Toth PP, Dearborn-Tomazos JL et al (2023a) Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol 43:e404\u2013e442. https:\/\/doi.org\/10.1161\/ATV.0000000000000164","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"4014_CR7","doi-asserted-by":"publisher","unstructured":"Amarenco P, Benavente O, Goldstein LB, Callahan A, Sillesen H, Hennerici MG et al (2009) Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial by Stroke Subtypes. Stroke [Internet] 40(4):1405\u20139. Available from: https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/STROKEAHA.108.534107","DOI":"10.1161\/STROKEAHA.108.534107"},{"key":"4014_CR8","doi-asserted-by":"publisher","unstructured":"The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. N Engl J Med 355(6):549\u201359. Available from: http:\/\/www.nejm.org\/doi\/https:\/\/doi.org\/10.1056\/NEJMoa061894","DOI":"10.1056\/NEJMoa061894"},{"key":"4014_CR9","doi-asserted-by":"crossref","unstructured":"Heuschmann PU, Kircher J, Nowe T, Dittrich R, Reiner Z, Cifkova R et al (2015) Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the EUROASPIRE III survey. Eur J Prev Cardiolog [Internet] 22(10):1354\u201362. Available from: https:\/\/academic.oup.com\/eurjpc\/article\/22\/10\/1354-1362\/5927056","DOI":"10.1177\/2047487314546825"},{"key":"4014_CR10","unstructured":"Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS et al (2018) AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary. Journal of the American College of Cardiology [Internet] 73(24):3168\u2013209. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109718390338"},{"key":"4014_CR11","doi-asserted-by":"publisher","unstructured":"Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H et al (2016) 2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J [Internet] 37(39):2999\u20133058. Available from: https:\/\/academic.oup.com\/eurheartj\/article-lookup\/doi\/https:\/\/doi.org\/10.1093\/eurheartj\/ehw272","DOI":"10.1093\/eurheartj\/ehw272"},{"key":"4014_CR12","doi-asserted-by":"publisher","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA et al (2017) Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med [Internet] 376(18):1713\u201322. Available from: http:\/\/www.nejm.org\/doi\/https:\/\/doi.org\/10.1056\/NEJMoa1615664","DOI":"10.1056\/NEJMoa1615664"},{"key":"4014_CR13","doi-asserted-by":"publisher","unstructured":"Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J et al (2015) Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events. N Engl J Med [Internet] 372(16):1500\u20139. Available from: http:\/\/www.nejm.org\/doi\/https:\/\/doi.org\/10.1056\/NEJMoa1500858","DOI":"10.1056\/NEJMoa1500858"},{"key":"4014_CR14","doi-asserted-by":"crossref","unstructured":"Koren MJ, Sabatine MS, Giugliano RP, Langslet G, Wiviott SD, Kassahun H et al (2017) Long-term Low-Density Lipoprotein Cholesterol\u2013Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia: Results Up to 4 Years From the Open-Label OSLER-1 Extension Study. JAMA Cardiol [Internet] 2(6):598. Available from:\u00a0http:\/\/cardiology.jamanetwork.com\/article.aspx?doi=10.1001\/jamacardio.2017.0747","DOI":"10.1001\/jamacardio.2017.0747"},{"key":"4014_CR15","doi-asserted-by":"publisher","unstructured":"Giugliano RP, Pedersen TR, Saver JL, Sever PS, Keech AC, Bohula EA et al (2020) Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. Stroke [Internet] 51(5):1546\u201354. Available from: https:\/\/www.ahajournals.org\/doi\/https:\/\/doi.org\/10.1161\/STROKEAHA.119.027759","DOI":"10.1161\/STROKEAHA.119.027759"},{"key":"4014_CR16","doi-asserted-by":"crossref","unstructured":"Marfella R, Prattichizzo F, Sardu C, Paolisso P, D\u2019Onofrio N, Scisciola L et al (2023) Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque. Atherosclerosis [Internet] 378:117180. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915023050748","DOI":"10.1016\/j.atherosclerosis.2023.06.971"},{"key":"4014_CR17","doi-asserted-by":"publisher","unstructured":"Karagiannis AD, Liu M, Toth PP, Zhao S, Agrawal DK, Libby P et al (2018) Pleiotropic Anti-atherosclerotic Effects of PCSK9 Inhibitors From Molecular Biology to Clinical Translation. Curr Atheroscler Rep [Internet] 20(4):20. Available from: http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s11883-018-0718-x","DOI":"10.1007\/s11883-018-0718-x"},{"key":"4014_CR18","doi-asserted-by":"crossref","unstructured":"Moustafa B, Oparowski D, Testai S, Guman I, Trifan G (2024) Efficacy and safety of PCSK9 inhibitors for stroke prevention: Systematic review and meta-analysis. Journal of Stroke and Cerebrovascular Diseases [Internet] 33(4):107633. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1052305724000788","DOI":"10.1016\/j.jstrokecerebrovasdis.2024.107633"},{"key":"4014_CR19","doi-asserted-by":"publisher","unstructured":"Huang YC, Chang CH, Tsai YH, Weng HH, Lin LC, Lee JD (2022) PCSK9 inhibition in patients with acute stroke and symptomatic intracranial atherosclerosis: protocol for a prospective, randomised, open-label, blinded end-point trial with vessel-wall MR imaging. BMJ Open [Internet] 12(4):e060068. Available from: https:\/\/bmjopen.bmj.com\/lookup\/doi\/https:\/\/doi.org\/10.1136\/bmjopen-2021-060068","DOI":"10.1136\/bmjopen-2021-060068"},{"key":"4014_CR20","doi-asserted-by":"publisher","unstructured":"Jeswani BM, Sharma S, Rathore SS, Nazir A, Bhatheja R, Kapoor K (2024) PCSK9 Inhibitors: The Evolving Future. Health Science Reports [Internet] 7(11):e70174. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/https:\/\/doi.org\/10.1002\/hsr2.70174","DOI":"10.1002\/hsr2.70174"},{"key":"4014_CR21","doi-asserted-by":"publisher","unstructured":"Van Bruggen FH, Nijhuis GBJ, Zuidema SU, Luijendijk H (2020) Serious adverse events and deaths in PCSK9 inhibitor trials reported on ClinicalTrials.gov: a systematic review. Expert Review of Clinical Pharmacology [Internet] 13(7):787\u201396. Available from: https:\/\/www.tandfonline.com\/doi\/full\/https:\/\/doi.org\/10.1080\/17512433.2020.1787832","DOI":"10.1080\/17512433.2020.1787832"},{"key":"4014_CR22","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"29","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ Published Online March 29:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ Published Online March"},{"key":"4014_CR23","doi-asserted-by":"publisher","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Reviews 5(1). https:\/\/doi.org\/10.1186\/s13643-016-0384-4","DOI":"10.1186\/s13643-016-0384-4"},{"key":"4014_CR24","unstructured":"Wells, George & Shea, Beverley & O\u2019Connell, D & Peterson, je & Welch, Vivian & Losos,M & Tugwell, Peter. (2000). The Newcastle\u2013Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis"},{"key":"4014_CR25","doi-asserted-by":"publisher","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366 l4898. Published 2019 Aug 28. https:\/\/doi.org\/10.1136\/bmj.l489","DOI":"10.1136\/bmj.l489"},{"issue":"3","key":"4014_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W (2010) Conducting meta-analyses in R with the metafor package. J Stat Softw 36(3):1\u201348. https:\/\/doi.org\/10.18637\/jss.v036.i03","journal-title":"J Stat Softw"},{"issue":"3","key":"4014_CR27","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3102\/10769986030003261","volume":"30","author":"W Viechtbauer","year":"2005","unstructured":"Viechtbauer W (2005) Bias and efficiency of meta-analytic variance estimators in the random-effects model. J Educ Behav Stat 30(3):261\u2013293. https:\/\/doi.org\/10.3102\/10769986030003261","journal-title":"J Educ Behav Stat"},{"key":"4014_CR28","doi-asserted-by":"crossref","unstructured":"Cochran WG The combination of estimates from different experiments. Biometrics, 10(1), 101\u2013129., Thompson SG (1954) (2002). Quantifying heterogeneity in a meta-analysis. Statistics in Medicine 21(11):1539\u20131558","DOI":"10.2307\/3001666"},{"key":"4014_CR29","doi-asserted-by":"crossref","unstructured":"Higgins, J. P. T., & Thompson, S. G. (2002). Quantifying heterogeneity in a meta-analysis. Statistics in Medicine, 21(11), 1539\u20131558.","DOI":"10.1002\/sim.1186"},{"key":"4014_CR30","doi-asserted-by":"publisher","first-page":"1454608","DOI":"10.3389\/fneur.2024.1454608","volume":"15","author":"X Qiu","year":"2024","unstructured":"Qiu X, Liang Y, Wei Y, Lu M, Mei Y, Tang S, Tang J, Liang J, Liang J (2024) Evolocumab for early reduction of LDL-C levels in patients with acute ischemic stroke: a randomized controlled trial. Front Neurol 15:1454608","journal-title":"Front Neurol"},{"issue":"6","key":"4014_CR31","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1136\/jnnp-2023-332392","volume":"95","author":"L Wu","year":"2024","unstructured":"Wu L, Zhang B, Li C, Zhuang Z, Liu K, Chen H, Zhu S, Zhu J, Dai Z, Huang H, Jiang Y (2024) PCSK9 inhibitors reduced early recurrent stroke in patients with symptomatic intracranial atherosclerotic stenosis. J Neurol Neurosurg Psychiatry 95(6):529\u2013535","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"4014_CR32","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40263-024-01145-5","volume":"39","author":"W Tian","year":"2025","unstructured":"Tian W, Cao H, Li X, Gong X, Yu X, Li D, Xie J, Bai Y, Zhang D, Li X, Xu P (2025) Adjunctive PCSK9 inhibitor Evolocumab in the prevention of early neurological deterioration in non-cardiogenic acute ischemic stroke: a multicenter, prospective, randomized, open-label, clinical trial. CNS Drugs 39(2):197\u2013208","journal-title":"CNS Drugs"},{"key":"4014_CR33","doi-asserted-by":"publisher","first-page":"1375609","DOI":"10.3389\/fneur.2024.1375609","volume":"15","author":"J Kim","year":"2024","unstructured":"Kim J, Hong U, Yoon CW, Bae JW, Rha JH, Park HK (2024) PCSK9 inhibitor in acute ischemic stroke patients receiving mechanical thrombectomy: early outcomes and safety. Front Neurol 15:1375609","journal-title":"Front Neurol"},{"issue":"2","key":"4014_CR34","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s11239-023-02925-4","volume":"57","author":"T Zhang","year":"2024","unstructured":"Zhang T, Zhang Y, Yang Y, Liao H, Li X, Liu R, Liu X, Yang L, Yue W (2024) Real-world effectiveness and safety of Evolocumab in very high-risk atherosclerotic cardiovascular disease patients with acute ischemic stroke. J Thromb Thrombolysis 57(2):302\u2013311","journal-title":"J Thromb Thrombolysis"},{"issue":"10","key":"4014_CR35","doi-asserted-by":"publisher","first-page":"e404","DOI":"10.1161\/ATV.0000000000000164","volume":"43","author":"LB Goldstein","year":"2023","unstructured":"Goldstein LB, Toth PP, Dearborn-Tomazos JL, Giugliano RP, Hirsh BJ, Pe\u00f1a JM et al (2023b) Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol 43(10):e404-42","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"4014_CR36","doi-asserted-by":"publisher","first-page":"e023328","DOI":"10.1161\/JAHA.121.023328","volume":"11","author":"E Punch","year":"2022","unstructured":"Punch E, Klein J, Diaba-Nuhoho P, Morawietz H, Garelnabi M (2022) Effects of PCSK9 targeting: alleviating oxidation, inflammation, and atherosclerosis. J Am Heart Assoc 11(3):e023328","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"4014_CR37","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","volume":"5","author":"AA Momtazi-Borojeni","year":"2019","unstructured":"Momtazi-Borojeni AA, Sabouri-Rad S, Gotto AM, Pirro M, Banach M, Awan Z et al (2019) PCSK9 and inflammation: a review of experimental and clinical evidence. Eur Heart J Cardiovasc Pharmacother 5(4):237\u2013245","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"25","key":"4014_CR38","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1161\/CIRCULATIONAHA.119.043826","volume":"140","author":"JW Jukema","year":"2019","unstructured":"Jukema JW, Zijlstra LE, Bhatt DL, Bittner VA, Diaz R, Drexel H et al (2019) Effect of Alirocumab on stroke in ODYSSEY OUTCOMES. Circulation 140(25):2054\u20132062","journal-title":"Circulation"},{"key":"4014_CR39","unstructured":"FOURIER Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo | tctmd.com [Internet]. [cited 2025 Sep 11]. Available from: https:\/\/www.tctmd.com\/news\/fourier-evolocumab-reduces-risk-cvd-events-15-compared-placebo"},{"issue":"6","key":"4014_CR40","doi-asserted-by":"publisher","first-page":"250","DOI":"10.5414\/CP204506","volume":"62","author":"K-H Shin","year":"2024","unstructured":"Shin K-H, Choi HD (2024) Primary and secondary prevention of stroke and cardiovascular events using Evolocumab and alirocumab: meta-analysis of randomized controlled trials. Int J Clin Pharmacol Ther 62(6):250\u2013258","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"4014_CR41","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12872-024-04057-w","volume":"24","author":"K Hosseini","year":"2024","unstructured":"Hosseini K, Soleimani H, Maleki S, Nasrollahizadeh A, Tayebi S, Nelson J et al (2024) Early administration of proprotein convertase subtilisin\/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis. BMC Cardiovasc Disord 24(1):395","journal-title":"BMC Cardiovasc Disord"},{"issue":"8","key":"4014_CR42","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.1016\/j.numecd.2021.03.026","volume":"31","author":"J Qin","year":"2021","unstructured":"Qin J, Liu L, Su XD, Wang BB, Fu BS, Cui JZ et al (2021) The effect of PCSK9 inhibitors on brain stroke prevention: A systematic review and meta-analysis. Nutr Metab Cardiovasc Dis 31(8):2234\u20132243","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"4","key":"4014_CR43","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1093\/ehjcvp\/pvae025","volume":"10","author":"SG Goodman","year":"2024","unstructured":"Goodman SG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R et al (2024) Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation. Eur Heart J Cardiovasc Pharmacother 10(4):342\u2013352","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"4014_CR44","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/eurjpc\/zwaa052","volume":"29","author":"Z Chen","year":"2022","unstructured":"Chen Z, Mo J, Xu J, Wang A, Dai L, Cheng A, Yalkun G, Meng X, Zhao X, Li H, Wu S, Wang Y (2022) Effects of individual and integrated cumulative burden of blood pressure, glucose, low-density lipoprotein cholesterol, and C-reactive protein on cardiovascular risk. Eur J Prev Cardiol 29(1):127\u2013135. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa052","journal-title":"Eur J Prev Cardiol"},{"issue":"12","key":"4014_CR45","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.scib.2023.05.028","volume":"68","author":"ZM Chen","year":"2023","unstructured":"Chen ZM, Gu HQ, Mo JL, Yang KX, Jiang YY, Yang X, Wang CJ, Xu J, Meng X, Jiang Y, Li H, Liu LP, Wang YL, Zhao XQ, Li ZX, Wang YJ (2023) U-shaped association between low-density lipoprotein cholesterol levels and risk of all-cause mortality mediated by post-stroke infection in acute ischemic stroke. Sci Bull Beijing 68(12):30\u20131335. https:\/\/doi.org\/10.1016\/j.scib.2023.05.028","journal-title":"Sci Bull Beijing"},{"issue":"6","key":"4014_CR46","doi-asserted-by":"publisher","first-page":"100713","DOI":"10.1016\/j.xinn.2024.100713","volume":"5","author":"ZM Chen","year":"2024","unstructured":"Chen ZM, Mo JL, Yang KX, Jiang YY, Wang CJ, Yang X, Jiang Y, Meng X, Xu J, Li H, Liu LP, Wang YL, Zhao XQ, Wang YJ, Gu HQ, Li ZX (2024) Beyond low-density lipoprotein cholesterol levels: impact of prior Statin treatment on ischemic stroke outcomes. Innov (Camb) 5(6):100713. https:\/\/doi.org\/10.1016\/j.xinn.2024.100713PMID: 39524491; PMCID: PMC11550173","journal-title":"Innov (Camb)"},{"key":"4014_CR47","unstructured":"PCSK9 inhibition mitigates vulnerable plaque\u2026 Biochemical Pharmacology [Internet]. [cited 2025 Sep 11]. Available from: https:\/\/www.ovid.com\/journals\/biopha\/abstract\/10.1016\/j.bcp.2025.117031~pcsk9-inhibition-mitigates-vulnerable-plaque-formation"},{"key":"4014_CR48","doi-asserted-by":"crossref","unstructured":"Basiak M, Kosowski M, Hachula M, Okopien B (2022) Impact of PCSK9 Inhibition on Proinflammatory cytokines and matrix metalloproteinases release in patients with mixed hyperlipidemia and vulnerable atherosclerotic plaque. Pharmaceuticals (Basel) 15(7)","DOI":"10.3390\/ph15070802"},{"issue":"2","key":"4014_CR49","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1161\/STROKEAHA.123.043633","volume":"55","author":"AM Wabnitz","year":"2024","unstructured":"Wabnitz AM, Turan TN (2024) Optimal medical management of atherosclerotic intracranial stenosis. Stroke 55(2):335\u2013343","journal-title":"Stroke"},{"key":"4014_CR50","doi-asserted-by":"publisher","first-page":"555","DOI":"10.2147\/VHRM.S275739","volume":"18","author":"X Jia","year":"2022","unstructured":"Jia X, Al Rifai M, Saeed A, Ballantyne CM, Virani SS (2022) Pcsk9 inhibitors in the management of cardiovascular risk: a practical guidance. Vasc Health Risk Manag 18:555\u2013566","journal-title":"Vasc Health Risk Manag"},{"issue":"4","key":"4014_CR51","doi-asserted-by":"publisher","first-page":"e060068","DOI":"10.1136\/bmjopen-2021-060068","volume":"12","author":"Y-C Huang","year":"2022","unstructured":"Huang Y-C, Chang C-H, Tsai Y-H, Weng H-H, Lin L-C, Lee J-D (2022) PCSK9 Inhibition in patients with acute stroke and symptomatic intracranial atherosclerosis: protocol for a prospective, randomised, open-label, blinded end-point trial with vessel-wall MR imaging. BMJ Open 12(4):e060068","journal-title":"BMJ Open"},{"issue":"1","key":"4014_CR52","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s13063-024-08709-2","volume":"26","author":"X Gong","year":"2025","unstructured":"Gong X, Yu X, Pu L, Jiao Y, Liu L, Cao H et al (2025) Effect of PCSK9 inhibitor on early neurological deterioration in acute ischemic stroke patients with a history of coronary heart disease: a study protocol for a randomized controlled trial in Dalian, China. Trials 26(1):7","journal-title":"Trials"},{"issue":"3","key":"4014_CR53","doi-asserted-by":"publisher","first-page":"310","DOI":"10.2174\/0115672026332171240624100802","volume":"21","author":"J Lei","year":"2024","unstructured":"Lei J, Fan Q, Chen X, Li W, Peng Y, Cai Y et al (2024) Effects of pcsk9 inhibitors on early neurologic deterioration in patients with acute non-cardioembolism without hemorrhagic transformation after intravenous thrombolysis. Curr Neurovasc Res 21(3):310\u20139","journal-title":"Curr Neurovasc Res"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04014-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04014-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04014-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:37:53Z","timestamp":1776404273000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04014-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,26]]},"references-count":53,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["4014"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04014-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,26]]},"assertion":[{"value":"21 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}